Anti‐craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence for SAEM GRACEJournal Articles
Overview
Research
Identity
View All
Overview
abstract
AbstractObjectivesAlcohol‐related concerns commonly present to the emergency department (ED), with a subset of individuals experiencing the symptoms of an alcohol use disorder (AUD). As such, examining the efficacy of pharmacological anti‐craving treatment for AUD in the ED is of increasing interest. The objective of this systematic review was to evaluate the direct evidence assessing the efficacy of providing anti‐craving medications for AUD treatment in the ED.MethodsA systematic search was conducted according to the patient‐intervention‐control‐outcome question: (P) adults (≥18 years old) presenting to the ED with an AUD (including suspected AUD); (I) anti‐craving medications (i.e., naltrexone, acamprosate, gabapentin); (C) no prescription or placebo; (O) reduction of repeat ED visits, engagement in addiction services, reductions in heavy drinking days, reductions in any drinking and amount consumed (or abstinence), and in relapse. Two reviewers independently assessed articles for inclusion and conducted risk of bias assessments for included studies.ResultsFrom 143 potentially relevant articles, 6 met inclusion criteria: 3 clinical trials, and 3 case studies. The clinical trials identified evaluated oral versus extended‐release naltrexone, monthly extended‐release naltrexone injections, and disulfiram. Both oral and extended‐release naltrexone resulted in decreased alcohol consumption. Monthly extended‐release naltrexone injections resulted in significant improvements in drinking and quality of life. Although out of scope, the disulfiram studies identified did not result in an improvement in drinking in comparison to no medication.ConclusionsOverall, there are few studies directly examining the efficacy of anti‐craving medications for AUD in the ED, although the limited evidence that exists is supportive of naltrexone pharmacotherapy, particularly extended‐release injection formulation. Additional randomized controlled trials are necessary for substantive direct evidence on anti‐craving medication initiation in the ED.
